Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amonafide L-Malate + Cytarabine in Secondary AML
NCT00273884Phase 2Completed
- Sponsor
- Xanthus Pharmaceuticals, Inc.
- Start
- Aug 2005
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of amonafide l-malate in acute myeloid leukemia (AML), sponsored by Xanthus Pharmaceuticals, Inc. Primary endpoint: Rate of Complete Remission with or without Complete Hematopoietic Recovery. Started Aug 2005; status: completed.
02
Drugs
amonafide l-malate
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00273884.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00273884.